SG11201606850QA - Specific sites for modifying antibodies to make immunoconjugates - Google Patents

Specific sites for modifying antibodies to make immunoconjugates

Info

Publication number: SG11201606850QA
Authority: SG; Singapore
Prior art keywords: specific sites; modifying antibodies; immunoconjugates; make; make immunoconjugates
Prior art date: 2014-03-12

Application number

SG11201606850QA

Inventor

Bernhard Hubert Geierstanger

Weijia Ou

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-11Application filed by Novartis AgfiledCriticalNovartis Ag

2016-09-29Publication of SG11201606850QApublicationCriticalpatent/SG11201606850QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

SG11201606850QA2014-03-122015-03-11Specific sites for modifying antibodies to make immunoconjugatesSG11201606850QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461952026P	2014-03-12	2014-03-12
PCT/US2015/019984WO2015138615A2 (en)	2014-03-12	2015-03-11	Specific sites for modifying antibodies to make immunoconjugates

Publications (1)

Publication Number	Publication Date
SG11201606850QAtrue SG11201606850QA (en)	2016-09-29

Family

ID=52737418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201606850QASG11201606850QA (en)	2014-03-12	2015-03-11	Specific sites for modifying antibodies to make immunoconjugates

Country Status (13)

Country	Link
US (1)	US20170021033A1 (en)
EP (2)	EP3960767A3 (en)
JP (2)	JP2017509337A (en)
KR (1)	KR20160125515A (en)
CN (1)	CN106659800A (en)
AU (1)	AU2015229463A1 (en)
BR (1)	BR112016020065A2 (en)
CA (1)	CA2940451A1 (en)
EA (1)	EA201691827A1 (en)
IL (1)	IL247306A0 (en)
MX (1)	MX2016011627A (en)
SG (1)	SG11201606850QA (en)
WO (1)	WO2015138615A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2953976T (en)	2013-02-08	2021-06-23	Novartis Ag	Specific sites for modifying antibodies to make immunoconjugates
WO2016020791A1 (en)*	2014-08-05	2016-02-11	Novartis Ag	Ckit antibody drug conjugates
KR20180018808A (en)	2015-06-22	2018-02-21	바이엘 파마 악티엔게젤샤프트	Antibody drug conjugates (ADC) and antibody precursor drug conjugates (APDC) with enzymatically cleavable groups
CN107921145A (en)*	2015-06-23	2018-04-17	拜耳医药股份有限公司	The antibody drug conjugate of KSP inhibitor and anti-TWEAKR antibody（ADC）
US11071788B2 (en)	2015-06-23	2021-07-27	Bayer Pharma Aktiengesellschaft	Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
JP6768011B2 (en)	2015-06-23	2020-10-14	バイエルファーマアクチエンゲゼルシャフト	Antibody drug conjugate with anti-CD123 antibody of kinesin spindle protein (KSP) inhibitor
WO2016207090A2 (en)	2015-06-23	2016-12-29	Bayer Pharma Aktiengesellschaft	Site specific homogeneous with ksp inhibitors
MA44334A (en)	2015-10-29	2018-09-05	Novartis Ag	ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
US11793880B2 (en)	2015-12-04	2023-10-24	Seagen Inc.	Conjugates of quaternized tubulysin compounds
WO2017096311A1 (en)	2015-12-04	2017-06-08	Seattle Genetics, Inc.	Conjugates of quaternized tubulysin compounds
EA201891482A1 (en)	2015-12-21	2018-12-28	Бристол-Маерс Сквибб Компани	MODIFIED ANTIBODIES FOR THE SITE-SPECIFIC CONJUGATION
CN109071634A (en)*	2016-04-26	2018-12-21	R.P.谢勒技术有限责任公司	Antibody coupling matter and its preparation and application
WO2017216028A1 (en)	2016-06-15	2017-12-21	Bayer Pharma Aktiengesellschaft	Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
KR20230066647A (en)	2016-06-17	2023-05-16	마젠타 테라퓨틱스 인코포레이티드	Compositions and methods for the depletion of cd117+cells
KR102726248B1 (en)	2016-07-07	2024-11-05	더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티	Antibody adjuvant conjugates
JOP20190155A1 (en)*	2016-12-21	2019-06-23	Novartis Ag	Antibody drug conjugates for ablating hematopoietic stem cells
CN110072556B (en)	2016-12-21	2023-05-02	拜耳制药股份公司	Specific antibody drug conjugates (ADCs) with KSP inhibitors
JP7066714B2 (en)	2016-12-21	2022-05-13	バイエル・ファルマ・アクティエンゲゼルシャフト	Antibody drug conjugate (ADC) with an enzymatically cleavable group
MX395639B (en)	2017-01-20	2025-03-25	Heidelberg Pharma Res Gmbh	COMPOSITIONS AND METHODS FOR CD137+ CELL DEPLETION.
JOP20190187A1 (en)	2017-02-03	2019-08-01	Novartis Ag	Anti-ccr7 antibody drug conjugates
AU2018227807B2 (en)	2017-02-28	2024-10-10	Seagen Inc.	Cysteine mutated antibodies for conjugation
AR111651A1 (en)	2017-04-28	2019-08-07	Novartis Ag	CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
EP3624854A1 (en)*	2017-05-16	2020-03-25	Université de Strasbourg	Protein-drug conjugates and their use in the treatment of cancers
CN110869394A (en)*	2017-06-16	2020-03-06	伊莱利利公司	Engineered antibody compounds and conjugates thereof
SG11202008821PA (en)*	2017-06-20	2020-10-29	Sichuan Baili Pharm Co Ltd	Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
US11364303B2 (en)*	2017-09-29	2022-06-21	Pfizer Inc.	Cysteine engineered antibody drug conjugates
WO2019111871A1 (en)	2017-12-05	2019-06-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
CN108743966B (en)*	2018-04-24	2021-10-19	四川百利药业有限责任公司	Cysteine engineered antibody-toxin conjugates
MX2020012495A (en)	2018-06-01	2021-02-15	Novartis Ag	Binding molecules against bcma and uses thereof.
AR115571A1 (en)*	2018-06-20	2021-02-03	Novartis Ag	DRUG ANTIBODY CONJUGATES FOR HEMATOPOIETIC STEM CELL ABLATION
JP7197297B2 (en)	2018-07-17	2022-12-27	シャープ株式会社	BASE STATION DEVICE, TERMINAL DEVICE, AND COMMUNICATION METHOD
SG11202102882YA (en)*	2018-09-28	2021-04-29	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule comprising altered antibody variable region
US20230053449A1 (en)	2018-10-31	2023-02-23	Novartis Ag	Dc-sign antibody drug conjugates
CA3123996A1 (en)	2018-12-21	2019-12-18	Novartis Ag	Antibodies to pmel17 and conjugates thereof
US20220072147A1 (en)*	2019-01-23	2022-03-10	AbTis Co., Ltd.	Compound for preparation of antibody-payload conjugate and use thereof
CN109928908B (en)*	2019-03-08	2022-05-03	联宁（苏州）生物制药有限公司	Preparation method and intermediate of drug-linker MC-MMAF for antibody drug conjugate
CN117843795A (en)*	2019-03-11	2024-04-09	凯惠科技发展(上海)有限公司	Cysteine-containing antibody, drug conjugate and application thereof
CA3130794A1 (en)	2019-03-15	2020-09-24	Bolt Biotherapeutics, Inc.	Immunoconjugates targeting her2
WO2020236817A2 (en)	2019-05-20	2020-11-26	Novartis Ag	Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN110642950B (en)*	2019-07-25	2021-10-01	广东新征程生命科学有限公司	Humanized T cell activated V domain immunosuppressive factor antigen binding fragment
KR20220148235A (en)*	2020-02-28	2022-11-04	젠자임 코포레이션	Modified Binding Polypeptides for Optimized Drug Conjugation
US20230203191A1 (en)*	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
AR121695A1 (en)	2020-03-31	2022-06-29	Chugai Pharmaceutical Co Ltd	MULTISPECIFIC ANTIGEN-BINDING MOLECULES TARGETING DLL3 AND THEIR USES
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
WO2022115451A1 (en)	2020-11-24	2022-06-02	Novartis Ag	Mcl-1 inhibitor antibody-drug conjugates and methods of use
AU2021386367A1 (en)	2020-11-24	2023-06-22	Les Laboratoires Servier	Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CA3200858A1 (en)	2020-11-24	2022-06-02	Novartis Ag	Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
BR112023021475A2 (en)	2021-04-16	2023-12-19	Novartis Ag	ANTIBODY-DRUG CONJUGATES AND METHODS FOR PRODUCING THEM
EP4422697A1 (en)	2021-10-29	2024-09-04	Bolt Biotherapeutics, Inc.	Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
TW202408588A (en)	2022-05-20	2024-03-01	瑞士商諾華公司	Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
CN119562832A (en)	2022-05-20	2025-03-04	诺华股份有限公司	MET BCL-XL inhibitor antibody-drug conjugates and methods of use thereof
KR20250027281A (en)	2022-05-20	2025-02-25	노파르티스 아게	EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of use thereof
KR20240001074A9 (en)*	2022-06-24	2024-11-13	주식회사 피노바이오	Antibody-drug conjugate in which two drug-linker conjugates are linked to one antibody
WO2024069235A2 (en)	2022-09-30	2024-04-04	Sixfold Bioscience Ltd.	Compositions containing oligonucleotides with theranostic applications
WO2024099368A1 (en)*	2022-11-08	2024-05-16	Westlake University	Peptide tags, compositions and methods for site-specific protein conjugation
WO2024189481A1 (en)	2023-03-10	2024-09-19	Novartis Ag	Panras inhibitor antibody-drug conjugates and methods of use thereof
CN118837542A (en)*	2023-04-24	2024-10-25	菲鹏生物股份有限公司	Antibodies and antibody conjugates and uses thereof
WO2025019790A1 (en)	2023-07-19	2025-01-23	Iovance Biotherapeutics, Inc.	Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2429008A (en)	1945-12-01	1947-10-14	Diamond Chain & Mfg Company	Sprocket or gear
US2429001A (en)	1946-12-28	1947-10-14	Axel H Stone	Artificial hand
EP0092918B1 (en)	1982-04-22	1988-10-19	Imperial Chemical Industries Plc	Continuous release formulations
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en)	1984-12-06	1992-07-07	Biomatrix, Inc.	Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en)	1985-06-26	1992-08-01	Liposome Co Inc	LIPOSOMAS COUPLING METHOD.
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US4880078A (en)	1987-06-29	1989-11-14	Honda Giken Kogyo Kabushiki Kaisha	Exhaust muffler
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
WO1991005548A1 (en)	1989-10-10	1991-05-02	Pitman-Moore, Inc.	Sustained release composition for macromolecular proteins
AU642932B2 (en)	1989-11-06	1993-11-04	Alkermes Controlled Therapeutics, Inc.	Protein microspheres and methods of using them
US5290540A (en)	1991-05-01	1994-03-01	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method for treating infectious respiratory diseases
US5714350A (en)	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en)	1992-03-12	1999-06-15	Alkermes Controlled Therapeutics, Inc.	Modulated release from biocompatible polymers
EP0563475B1 (en)	1992-03-25	2000-05-31	Immunogen Inc	Cell binding agent conjugates of derivatives of CC-1065
EP0640094A1 (en)	1992-04-24	1995-03-01	The Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5934272A (en)	1993-01-29	1999-08-10	Aradigm Corporation	Device and method of creating aerosolized mist of respiratory drug
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US6132764A (en)	1994-08-05	2000-10-17	Targesome, Inc.	Targeted polymerized liposome diagnostic and treatment agents
DE69630514D1 (en)	1995-01-05	2003-12-04	Univ Michigan	SURFACE-MODIFIED NANOPARTICLES AND METHOD FOR THEIR PRODUCTION AND USE
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6121022A (en)	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6019968A (en)	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
JP2000507912A (en)	1995-08-31	2000-06-27	アルカームズコントロールドセラピューティックス，インコーポレイテッド	Sustained release composition of active agent
DK0885002T3 (en)	1996-03-04	2011-08-22	Penn State Res Found	Materials and methods for enhancing cellular internalization
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
ES2236832T3 (en)	1997-01-16	2005-07-16	Massachusetts Institute Of Technology	PREPARATION OF PARTICLES FOR INHALATION.
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en)	1997-05-21	2006-03-08	Biovation Limited	Method for the production of non-immunogenic proteins
ATE386802T1 (en)	1997-06-12	2008-03-15	Novartis Int Pharm Ltd	ARTIFICIAL ANTIBODIES POLYPEPTIDES
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
SE512663C2 (en)	1997-10-23	2000-04-17	Biogram Ab	Active substance encapsulation process in a biodegradable polymer
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1089712B1 (en)	1998-06-24	2003-05-02	Advanced Inhalation Research, Inc.	Large porous particles emitted from an inhaler
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
PT1242401E (en)	1999-11-24	2007-03-30	Immunogen Inc	Cytotoxic agents comprising taxanes and their therapeutic use
JP2003531821A (en)	1999-12-29	2003-10-28	イムノージェンインコーポレーテッド	Cytotoxic drugs containing modified doxorubicin and daunorubicin and their therapeutic use
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
CN1922199B (en)*	2003-07-21	2013-10-30	伊缪诺金公司	CA6 antigen-specific cytotoxic conjugate and methods of using same
US20100111856A1 (en)*	2004-09-23	2010-05-06	Herman Gill	Zirconium-radiolabeled, cysteine engineered antibody conjugates
ES2669510T3 (en)*	2004-09-23	2018-05-28	Genentech, Inc.	Antibodies and conjugates engineered with cysteine
WO2008020827A2 (en)*	2005-08-01	2008-02-21	Biogen Idec Ma Inc.	Altered polypeptides, immunoconjugates thereof, and methods related thereto
KR20080080482A (en)	2005-09-07	2008-09-04	메디뮨 엘엘씨	EPH receptor receptor conjugated with toxin
US20110033378A1 (en)*	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
BRPI0919932A8 (en)*	2008-10-24	2018-02-06	Novartis Ag	BIOSYNTHETICLY GENERATED PYRROLIN-CARBOXY-LYSINE, AS WELL AS A PROCESS FOR PREPARING A METHOD FOR DERIVATIZING A PROTEIN
US8466260B2 (en)*	2009-04-01	2013-06-18	Genentech, Inc.	Anti-FcRH5 antibodies and immunoconjugates and methods of use
TWI540132B (en)*	2009-06-08	2016-07-01	亞培公司	Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
BRPI1015234A2 (en)	2009-06-22	2018-02-20	Medimmune Llc	fc regions designed for site specific conjugation.
GB0920127D0 (en)*	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
EP3539982B1 (en)*	2011-12-23	2025-02-19	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
KR101515894B1 (en)	2012-02-20	2015-05-19	주식회사 노리코리아	Method, system and computer-readable recording medium for providing educational services based on knowledge units
PT2953976T (en)*	2013-02-08	2021-06-23	Novartis Ag	Specific sites for modifying antibodies to make immunoconjugates
SG11201604877UA (en)*	2013-12-17	2016-07-28	Novartis Ag	Cytotoxic peptides and conjugates thereof
US11605302B2 (en)	2020-11-10	2023-03-14	Rockwell Collins, Inc.	Time-critical obstacle avoidance path planning in uncertain environments

2015
- 2015-03-11WOPCT/US2015/019984patent/WO2015138615A2/enactiveApplication Filing
- 2015-03-11BRBR112016020065Apatent/BR112016020065A2/ennot_activeIP Right Cessation
- 2015-03-11CACA2940451Apatent/CA2940451A1/ennot_activeAbandoned
- 2015-03-11SGSG11201606850QApatent/SG11201606850QA/enunknown
- 2015-03-11KRKR1020167027917Apatent/KR20160125515A/ennot_activeCeased
- 2015-03-11EPEP21177819.6Apatent/EP3960767A3/enactivePending
- 2015-03-11AUAU2015229463Apatent/AU2015229463A1/ennot_activeAbandoned
- 2015-03-11CNCN201580012982.9Apatent/CN106659800A/enactivePending
- 2015-03-11USUS15/124,606patent/US20170021033A1/ennot_activeAbandoned
- 2015-03-11EPEP15712236.7Apatent/EP3129407A2/ennot_activeCeased
- 2015-03-11JPJP2016556788Apatent/JP2017509337A/ennot_activeWithdrawn
- 2015-03-11EAEA201691827Apatent/EA201691827A1/enunknown
- 2015-03-11MXMX2016011627Apatent/MX2016011627A/enunknown
2016
- 2016-08-16ILIL247306Apatent/IL247306A0/enunknown
2018
- 2018-03-23JPJP2018056669Apatent/JP2018134080A/enactivePending

Also Published As

Publication number	Publication date
IL247306A0 (en)	2016-09-29
CA2940451A1 (en)	2015-09-17
EP3960767A2 (en)	2022-03-02
EP3129407A2 (en)	2017-02-15
MX2016011627A (en)	2016-11-29
BR112016020065A2 (en)	2018-02-20
WO2015138615A3 (en)	2015-12-03
WO2015138615A2 (en)	2015-09-17
KR20160125515A (en)	2016-10-31
JP2017509337A (en)	2017-04-06
EA201691827A1 (en)	2017-01-30
US20170021033A1 (en)	2017-01-26
EP3960767A3 (en)	2022-06-01
CN106659800A (en)	2017-05-10
AU2015229463A1 (en)	2016-09-15
JP2018134080A (en)	2018-08-30

Publication	Publication Date	Title
IL285287A (en)	2021-09-30	Antibodies to tigit
IL247306A0 (en)	2016-09-29	Specific sites for modifying antibodies to make immunoconjugates
IL261188A (en)	2018-10-31	Antibodies to tigit
IL267798B (en)	2020-09-30	Human antibodies to pd-1
IL250583A0 (en)	2017-04-30	Anti-tigit antibodies
HK1213580A1 (en)	2016-07-08	Specific sites for modifying antibodies to make immunoconjugates
SG11201703403TA (en)	2017-05-30	Anti-tim-3 antibodies
SG11201703346PA (en)	2017-05-30	Anti-tim-3 antibodies
PT3129406T (en)	2019-04-24	Conjugated compounds comprising cysteine-engineered antibodies
GB201411420D0 (en)	2014-08-13	Antibody constructs
IL252422B (en)	2018-06-28	Effector-deficient anti-cd32a antibodies
IL250374B (en)	2021-04-29	Anti-ceramide antibodies
GB201609742D0 (en)	2016-07-20	Improvements relating to antibodies
GB201419089D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201419092D0 (en)	2014-12-10	Anti-TIM-3 antibodies
GB201417614D0 (en)	2014-11-19	Antibodies
GB201414270D0 (en)	2014-09-24	Antibodies
GB201405775D0 (en)	2014-05-14	Antibodies
GB201401200D0 (en)	2014-03-12	Antibodies

Movatterモバイル変換

SG11201606850QA - Specific sites for modifying antibodies to make immunoconjugates - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=52737418

Family Applications (1)

Country Status (13)

Families Citing this family (58)

Family Cites Families (65)

Also Published As

Similar Documents